Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Tuesdays: X-article on biotech hot topics
Wednesdays: Podcast format of X-article
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Saturdays: Podcast format of Weekly News Update
Sundays: Building Biotech: Strategic Topics
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
As the biotech industry charges into 2025, the opportunities and challenges ahead promise to reshape the landscape of medicine and innovation. In this special episode, we’re diving into 25 bold predictions for the coming year—covering everything from breakthrough therapies and emerging technologies to paradigm shifts in drug development and regulatory landscapes. Whether it’s the rise of epigenetic editing, the continued evolution of oral GLP-1 agonists, or the expansion of in-vivo CAR-T, our projections offer a thought-provoking glimpse into biotech’s near future. So buckle up and join us as we map out the transformative trends that will define the next chapter of this incredible field. Let’s get started!
📣🎙️ TODAY’S POCAST:
( 0:07 ): Intro
( 1:16 ): Blockbuster hopes: Long COVID, cachexia, and bispecific antibodies
( 4:23 ): Evolution of CAR-T and the promise of in vivo therapies
( 6:02 ): RNA technology and the rise of private equity over IPOs
( 8:09 ): AI in biotech: tempered expectations and clinical progress
( 9:11 ): LNP breakthroughs: beyond the liver, targeting lungs and T cells
( 11:34 ): Aging therapies: cellular senescence and epigenetic reprogramming
( 13:55 ): Obesity treatment: exploring new pathways like INHBE and GPCRs
( 14:05 ): Challenges for ADCs and mRNA delivery beyond vaccines
( 15:17 ): Regulatory shifts: FDA’s response to accelerated approval backlash
( 16:30 ): Wild cards: gene writing, psychedelics, and immune resetting
( 20:00 ): Wrap up
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post